Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study
Phase 2 trial shows improved overall survival in newly diagnosed multiple myeloma patients with renal impairment, highlighting the role of treatment response.
Key Points
Evaluate the long-term survival outcomes of pomalidomide/bortezomib/dexamethasone in patients with newly diagnosed multiple myeloma and renal impairment.
Conducted a prospective, open-label, phase 2 trial with 61 patients with NDMM and renal impairment.
Patients received up to 9 cycles of PVD induction therapy, with options for autologous stem cell transplantation.
Primary endpoint was 3-month renal response according to IMWG criteria; secondary endpoints included progression-free survival and overall survival.
After 42 months of follow-up, 3-year overall survival rate was 80.2% and 3-year progression-free survival rate was 74.4%.
Renal response was associated with significantly improved overall survival (HR 0.327; P=0.029).
54.1% of patients completed planned therapy, and no new long-term safety signals were observed.